Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome
Author
dc.contributor.author
Urzúa Salinas, Cristhian
Author
dc.contributor.author
Vásquez, Darío H.
Author
dc.contributor.author
Huidobro, Andres
Author
dc.contributor.author
Hernandez, Helio
Author
dc.contributor.author
Alfaro, Jorge
Admission date
dc.date.accessioned
2019-03-11T13:19:40Z
Available date
dc.date.available
2019-03-11T13:19:40Z
Publication date
dc.date.issued
2012
Cita de ítem
dc.identifier.citation
Current Eye Research, Volumen 37, Issue 8, 2018, Pages 684-688
Identifier
dc.identifier.issn
02713683
Identifier
dc.identifier.issn
14602202
Identifier
dc.identifier.other
10.3109/02713683.2012.674609
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165698
Abstract
dc.description.abstract
Purpose: To determine symptoms improvement in dry eye patients with short-term autologous serum (AS) eyedrops treatment using the standardized Ocular Surface Disease Index (OSDI) survey. Materials and methods: A double-blind randomized crossover clinical trial was conducted, comparing short-term (2 weeks) topical treatment with AS eyedrops diluted at 20% versus conventional artificial tears treatment in adult severe dry eye syndrome (DES) patients. The main outcome measure was assessment of symptoms with OSDI survey. Secondary outcomes were corneal and conjunctival fluorescein staining score of OXFORD and tear break up time (TBUT). The protocol was registered in www.clinicaltrials.gov, ID number: NCT00779987. Results: Twelve severe DES patients were included. Autologous serum treatment showed a statistically significant (p = 0.002) higher OSDI decrease (50%) versus conventional treatment (22%). There were no significant changes in objectives parameters (OXFORD and TBUT). Conclusions: S